Caleb Lauber, MD
Family Medicine · Albuquerque, NMNPI 1205802642
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Novo Nordisk at 39.0% of the total. Reporting peaked in 2023 at $1,574 and has fallen 94.2% since, to $91 in 2025. Among family medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $38.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Astellas Pharma US Inc$447
- AVEO Pharmaceuticals, Inc.$194
- Eisai Inc.$132
- Novartis$126
- Johnson & Johnson$126
- plus $1K from 28 others
What the payments were for
- Consulting fees$1,30539%
- Food & beverage$1,61848%
- Education$42013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $1,305 |
| Astellas Pharma US Inc | 19 | $447 |
| AVEO Pharmaceuticals, Inc. | 3 | $194 |
| Eisai Inc. | 6 | $132 |
| Novartis | 5 | $126 |
| Johnson & Johnson | 5 | $126 |
| Seagen Inc. | 4 | $120 |
| AstraZeneca | 4 | $103 |
| Sanofi | 3 | $79 |
| Genentech USA, Inc. | 3 | $65 |
| Pharmaessentia USA Corporation | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Merck | 2 | $45 |
| Bristol Myers Squibb | 2 | $44 |
| Exelixis Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $38 |
| Pfizer | 2 | $32 |
| Beigene USA, Inc. | 2 | $31 |
| GSK | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| EMD Serono, Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Legend Biotech USA Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Bayer | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$3,344 in reported general payments places this provider in the 90th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $29,649 |
| XareltoRivaroxaban | 19 | $21,111 |
| OzempicSemaglutide | 15 | $14,227 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $3,902 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,423 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $2,548 |
| Levothyroxine Sodium | 122 | $2,410 |
| Pravastatin Sodium | 114 | $2,134 |
| Pregabalin | 24 | $2,010 |
| Fentanyl | 14 | $1,846 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $1,374 |
| Losartan Potassium | 130 | $1,306 |
| Atorvastatin Calcium | 75 | $1,244 |
| Gabapentin | 85 | $1,152 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $29,64929 claims |
| Johnson & JohnsonXarelto | $126 | $21,11119 claims |
| Novo NordiskOzempic | $1,305 | $14,22715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Albuquerque
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Michael MontoyaAlbuquerque$7K
- Yvonne Vanarsdale-ImaniAlbuquerque$7K
- Donald OrtizAlbuquerque$7K
- Satkirin KhalsaAlbuquerque$6K
- Angela RomeroAlbuquerque$5K
- H Preston MatthewsAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.